<DOC>
	<DOCNO>NCT00002474</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , carboplatin , mitoxantrone , work different way stop growth tumor cell , either kill cell stop divide . Giving chemotherapy autologous bone marrow transplant may allow doctor give high dos chemotherapy kill tumor cell . PURPOSE : This phase II trial study well chemotherapy autologous bone marrow transplant work treat patient refractory recurrent ovarian cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Bone Marrow Transplant Treating Patients With Refractory Recurrent Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate , duration response , overall survival patient refractory relapse ovarian epithelial cancer treat high-dose cyclophosphamide , carboplatin , mitoxantrone follow autologous bone marrow transplantation . - Determine nonhematopoietic toxicity regimen patient . OUTLINE : Autologous bone marrow harvest study entry . Patients receive high-dose cyclophosphamide IV 1 hour mitoxantrone IV 15 minute day -8 , -6 , -4 carboplatin IV continuously day -8 -3 absence unacceptable toxicity . Bone marrow reinfused day 0 begin least 60 hour completion carboplatin infusion . Patients follow survival . PROJECTED ACCRUAL : A total 15-30 patient accrue study within 1.5-3 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis refractory relapse ovarian epithelial cancer Must fail prior regimen contain cisplatin carboplatin Bidimensionally measurable evaluable disease Serial CA125 antigen titer cytologically positive pleural effusion and/or ascites acceptable evaluable disease Autologous bone marrow harvest great 1.2 x 10 eighth nucleate cells/kg require study entry No evidence tumor marrow harvest sit bilateral bone marrow aspirate biopsy , pelvic xray , bone scan CNS involvement allow PATIENT CHARACTERISTICS : Age : Under 65 Performance status : SWOG 02 Life expectancy : At least 8 week Hematopoietic : WBC great 3,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 10.0 g/dL Hepatic : Bilirubin le 2.0 mg/dL SGOT SGPT less 2 time upper limit normal Renal : Creatinine clearance great 60 mL/min No prior hemorrhagic cystitis Cardiovascular : LVEF great 45 % MUGA scan Other : No hearing loss voice tone No active infection No psychological contraindication study treatment Not pregnant Negative pregnancy test HIV negative General medical condition must allow general anesthesia PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior bone marrow transplantation More 4 week since prior biologic therapy recover Chemotherapy : See Disease Characteristics More 4 week since prior chemotherapy ( least 6 week nitrosoureas mitomycin ) recover Endocrine therapy : Not specify Radiotherapy : More 4 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>